Northwest Biotherapeutics, Inc. (NWBO) ended last trading session with a change of 15.71 percent. It trades at an average volume of 2.11M shares versus 2.27M shares recorded at the end of last trading session. The share price of $0.41 is at a distance of 26.56 percent from its 52-week low and down -85.54 percent versus its peak. The company has a market cap of $50.49M and currently has 124.66M shares outstanding. The share price is currently -12.24 percent versus its SMA20, -14.87 percent versus its SMA50, and -40.76 percent versus its SMA200. The stock has a weekly performance of 16.35 percent and is 16.35 percent year-to-date as of the recent close.
Dec. 20, 2016 — Northwest Biotherapeutics, Inc. (NWBO), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced that it has entered into definitive agreements with institutional investors for a registered direct offering with gross proceeds of $10 million.
The Company will sell to the investors approximately 28.6 million shares of common stock at a purchase price of $.35 per share resulting in gross proceeds to the Company of $10 million. The investors will also receive warrants to purchase up to approximately 14.3 million shares of common stock with an exercise price of $.35 per share and an exercise period of 5 years.
Agios Pharmaceuticals, Inc. (AGIO) recently recorded -9.94 percent change and currently at $42.78 is 27.7 percent away from its 52-week low and down -36.85 percent versus its peak. It has a past 5-day performance of 2.52 percent and trades at an average volume of 815.53K shares. The stock has a 1-month performance of -8.43 percent and is 2.52 percent year-to-date as of the recent close. There were about 40.71M shares outstanding which made its market cap $1.74B. The share price is currently -7.68 percent versus its SMA20, -18.41 percent versus its SMA50, and -11.11 percent versus its SMA200.
Jan. 09, 2017 — Agios Pharmaceuticals, Inc. (AGIO), a leader in the fields of cancer metabolism and rare genetic metabolic diseases, outlined key 2017 milestones in conjunction with its presentation at the 35th Annual J.P. Morgan Healthcare Conference in San Francisco. The presentation will outline important milestones as Agios evolves into a commercial stage company, including potential launches for enasidenib and AG-120 in R/R AML, pivotal development for its second wholly owned asset, AG-348 in pyruvate kinase (PK) deficiency, and an investigational new drug (IND) application submission for the company’s next development candidate, focused on MTAP deleted cancers. The company will webcast its presentation on Monday, January 9, 2017 at 10:00 a.m. PT (1:00 p.m. ET) at www.agios.com.